Patents Examined by Jessica H. Roark
  • Antibody therapeutics that bind CD123
    Patent number: 10100118
    Abstract: There is disclosed compositions and methods relating to or derived from anti-CD123 antibodies. More specifically, there is disclosed fully human antibodies that bind CD123, CD123-antibody binding fragments and derivatives of such antibodies, and CD123-binding polypeptides comprising such fragments. Further still, there is disclosed nucleic acids encoding such antibodies, antibody fragments and derivatives and polypeptides, cells comprising such polynucleotides, methods of making such antibodies, antibody fragments and derivatives and polypeptides, and methods of using such antibodies, antibody fragments and derivatives and polypeptides, including methods of treating a disease.
    Type: Grant
    Filed: April 8, 2016
    Date of Patent: October 16, 2018
    Assignee: Sorrento Therapeutics, Inc.
    Inventors: Heyue Zhou, John Dixon Gray
  • Chimeric antigen receptor containing a toll-like receptor intracellular domain
    Patent number: 10093717
    Abstract: The present invention relates to a chimeric antigen receptor, a nucleic acid encoding the same and a cell expressing the same, and their use in manufacturing drugs for treating tumors. The chimeric antigen receptor of the present invention is characterized by its intracellular domain including at least Toll-like receptor 1 and/or Toll-like receptor 2 intracellular domain(s); compared to the prior art, the chimeric antigen receptors of the present invention has significant advantages in T cell expansion, cytotoxicity, T cell invasion and migration, eliminating immunosuppressive effect of regulatory T cells and promoting the formation of memory T cells, etc.
    Type: Grant
    Filed: August 7, 2015
    Date of Patent: October 9, 2018
    Assignee: SHENZHEN IN VIVO BIOMEDICINE TECHNOLOGY LIMITED COMPANY
    Inventors: Peng Li, Yunxin Lai, Simiao Lin, Yao Yao
  • Glypican-3 antibody and uses thereof
    Patent number: 10093746
    Abstract: The present invention relates to compositions and methods of isolated polynucleotides that encode or polypeptides comprising glypican-3 (GPC3). The invention also includes a chimeric antigen receptor (CAR) wherein the CAR is able to target GPC3. The invention further includes methods of treating a subject or diagnosing and treating diseases, disorders or conditions associated with dysregulated glypican-3.
    Type: Grant
    Filed: September 3, 2015
    Date of Patent: October 9, 2018
    Assignees: The Trustees of the University of Pennsylvania, The United States of America as represented by the Department of Veterans Affairs
    Inventor: David Kaplan
  • Anti-claudin antibodies and methods of use
    Patent number: 10053511
    Abstract: Provided herein are anti-CLDN antibodies and antibody drug conjugates (ADC), including derivatives thereof, and methods of using the same to treat proliferative disorders.
    Type: Grant
    Filed: November 5, 2014
    Date of Patent: August 21, 2018
    Assignee: AbbVie Stemcentrx LLC
    Inventors: Marianne Santaguida, Monette Aujay, Laura Saunders, David Liu, Orit Foord, Robert A. Stull, Paul Anthony Escarpe
  • Combination therapy with CD4 lymphocyte depletion and MTOR inhibitors
    Patent number: 10039825
    Abstract: The invention provides methods for treating a malignant neoplastic cell proliferative disorder or disease, comprising administering to a subject in need thereof an effective amount of an mTOR inhibitor and an effective amount of a CD4 lymphocyte depleting agent. Such methods find utility in the treatment of certain subsets of malignant neoplastic cell proliferative disorders or diseases, e.g. renal cell carcinoma and melanoma. The invention also provides for pharmaceutical compositions comprising a therapeutically effective amount of an mTOR inhibitor and an effective amount of a CD4 lymphocyte depleting agent in a pharmaceutically acceptable carrier.
    Type: Grant
    Filed: July 25, 2016
    Date of Patent: August 7, 2018
    Assignee: Cedars-Sinai Medical Center
    Inventors: Hyung Kim, Yanping Wang
  • Thymic stromal lymphopoietin (TSLP)-binding molecules and methods of using the molecules
    Patent number: 10000561
    Abstract: The invention provides molecules, e.g., antibodies or antibody fragments, that specifically bind thymic stromal lymphopoietin (TSLP), compositions comprising these molecules, and methods of using and producing these molecules.
    Type: Grant
    Filed: September 7, 2016
    Date of Patent: June 19, 2018
    Assignee: NOVARTIS AG
    Inventors: Matthew John Edwards, Jean-Michel Rene Rondeau, Danforth Miller, Daniel Huang, Hans-Peter Knopf, Gino Anselmus Van Heeke, Rene Hemmig, Kapil Gupta, Nicole Haubst, Barbara Andlauer
  • Coiled coil and/or tether containing protein complexes and uses thereof
    Patent number: 9994646
    Abstract: The invention provides engineered protein complexes constructed using a coiled coil and/or a tether and methods for making, using, and purifying such complexes, such as multispecific antibodies or other multispecific Fc containing complexes.
    Type: Grant
    Filed: June 9, 2015
    Date of Patent: June 12, 2018
    Assignee: Genentech, Inc.
    Inventors: Erin H. Christensen, Dan L. Eaton, Andrew C. Vendel, Bernd Wranik
  • Pharmaceutical composition for treatment and prevention of cancers
    Patent number: 9982059
    Abstract: The present invention relates to a pharmaceutical composition for treatment and/or prevention of cancer, which comprises, as an active ingredient, an antibody or fragment thereof having an immunological reactivity with a CAPRIN-1 protein or a fragment thereof comprising 7 or more consecutive amino acids.
    Type: Grant
    Filed: April 6, 2016
    Date of Patent: May 29, 2018
    Assignee: TORAY INDUSTRIES, INC.
    Inventors: Fumiyoshi Okano, Takayoshi Ido, Takanori Saito, Shinichi Kobayashi
  • Immunological reagents
    Patent number: 9982053
    Abstract: This disclosure relates to binding agents with specificity for programmed cell death 1 (PD-1) and to methods for using the same to treat, prevent and/or ameliorate an infectious disease (e.g., human immunodeficiency virus (HIV)), cancer and/or autoimmunity.
    Type: Grant
    Filed: August 5, 2015
    Date of Patent: May 29, 2018
    Assignee: MabQuest, SA
    Inventors: Giuseppe Pantaleo, Craig Fenwick
  • Immunological reagents
    Patent number: 9982052
    Abstract: This disclosure relates to binding agents with specificity for programmed cell death 1 (PD-1) and to methods for using the same to treat, prevent and/or ameliorate an infectious disease (e.g., human immunodeficiency virus (HIV)), cancer and/or autoimmunity. In addition, this disclosure identifies a novel binding patch (“P2”) on PD-1 that is linked with a previously unidentified functional activity of PD-1 that is distinct from the interaction site involved with either the PD-L1 or PD-L2 ligands. Furthermore, we demonstrate that antibodies that interact with this region of PD-1 are able to act as antagonists of PD-1 and that this antagonism is further enhanced with the addition of antibodies that act through the blockade of the PD-1/PD-L1/L2 interaction.
    Type: Grant
    Filed: September 22, 2016
    Date of Patent: May 29, 2018
    Assignee: MabQuest, SA
    Inventors: Giuseppe Pantaleo, Craig Fenwick
  • Anti-Axl antibodies
    Patent number: 9975953
    Abstract: Antibodies which specifically bind to the Ax I protein are described. Also disclosed are methods for the production and use of the anti-Axl antibodies.
    Type: Grant
    Filed: June 18, 2015
    Date of Patent: May 22, 2018
    Assignee: BerGenBio ASA
    Inventors: David Robert Micklem, Sergej Kiprijanov, Linn Hodneland Nilsson, Lavina Ahmed, Hallvard Haugen
  • Cytotoxicity-inducing theraputic agent
    Patent number: 9975966
    Abstract: Novel multispecific antigen-binding molecules maintaining excellent cellular cytotoxicity and high stability, which comprise a domain that contains an antibody variable region having glypican 3-binding activity and a domain that contains an antibody variable region having T-cell receptor complex-binding activity, were discovered. Since the molecules of the present invention show a strong cytotoxicity against cells and tissues expressing glypican 3, it is possible to produce novel pharmaceutical compositions for treating or preventing various cancers.
    Type: Grant
    Filed: March 23, 2017
    Date of Patent: May 22, 2018
    Assignee: Chugai Seiyaku Kabushiki Kaisha
    Inventors: Junichi Nezu, Atsushi Narita, Takahiro Ishiguro, Mika Sakurai, Hirotake Shiraiwa, Naoka Hironiwa, Tomoyuki Igawa, Yumiko Kawai
  • Anti-Axl antibodies
    Patent number: 9975954
    Abstract: Antibodies characterized by their variable sequences/CDRs which specifically bind to the Axl protein are described. Also disclosed are methods for the production and use of the anti-Axl antibodies.
    Type: Grant
    Filed: June 18, 2015
    Date of Patent: May 22, 2018
    Assignee: BerGenBio ASA
    Inventors: David Robert Micklem, Sergej Kiprijanov, Linn Hodneland Nilsson, Lavina Ahmed, Hallvard Haugen
  • Amino acid sequences directed against HER2 and polypeptides comprising the same for the treatment of cancers and/or tumors
    Patent number: 9969805
    Abstract: The present invention relates to amino acid sequences and Nanobodies that are directed against Epidermal Growth Factor Receptor 2 (HER2), as well as to compounds or constructs, and in particular proteins and polypeptides, that comprise or essentially consist of one or more such amino acid sequences.
    Type: Grant
    Filed: January 8, 2015
    Date of Patent: May 15, 2018
    Assignee: Ablynx N.V.
    Inventors: Hilde Adi Pierrette Revets, Carlo Boutton, Hendricus Renerus Jacobus Mattheus Hoogenboom
  • Antibody therapeutics that bind CD123
    Patent number: 9969807
    Abstract: There is disclosed compositions and methods relating to or derived from anti-CD123 antibodies. More specifically, there is disclosed fully human antibodies that bind CD123, CD123-antibody binding fragments and derivatives of such antibodies, and CD123-binding polypeptides comprising such fragments. Further still, there is disclosed nucleic acids encoding such antibodies, antibody fragments and derivatives and polypeptides, cells comprising such polynucleotides, methods of making such antibodies, antibody fragments and derivatives and polypeptides, and methods of using such antibodies, antibody fragments and derivatives and polypeptides, including methods of treating a disease.
    Type: Grant
    Filed: April 8, 2016
    Date of Patent: May 15, 2018
    Assignee: Sorrento Therapeutics, Inc.
    Inventors: John Dixon Gray, Heyue Zhou
  • Anti-CEP antibody or fragment thereof
    Patent number: 9957333
    Abstract: An isolated anti-carboxyethylpyrrole (anti-CEP) antibody or antigen binding portion thereof includes a heavy chain variable domain that includes three CDRs having at least 90% sequence identity to the three heavy chain CDRs of SEQ ID NO: 7, and a light chain variable domain that includes three CDRs having at least 90% sequence identity to the three light chain CDRs of SEQ ID NO: 8.
    Type: Grant
    Filed: April 17, 2015
    Date of Patent: May 1, 2018
    Assignees: Case Western Reserve University, The Cleveland Clinic Foundation
    Inventors: Robert G. Salomon, John W. Crabb, Yalun Cui, Nicholas D. Tomko
  • Antibodies against human CD38
    Patent number: 9944711
    Abstract: Isolated monoclonal antibodies which bind to human CD38 and related antibody-based compositions and molecules, are disclosed. Also disclosed are pharmaceutical compositions comprising the antibodies and therapeutic and diagnostic methods for using the antibodies.
    Type: Grant
    Filed: January 8, 2016
    Date of Patent: April 17, 2018
    Assignee: GENMAB A/S
    Inventors: Michel De Weers, Tim Walseth, Jan Van De Winkel, Tom Vink, Paul Parren
  • CD123 specific chimeric antigen receptors for cancer immunotherapy
    Patent number: 9944709
    Abstract: The present invention relates to Chimeric Antigen Receptors (CAR) that are recombinant chimeric proteins able to redirect immune cell specificity and reactivity toward selected membrane antigens, and more particularly in which extracellular ligand binding is a scFV derived from a CD123 monoclonal antibody, conferring specific immunity against CD123 positive cells. The engineered immune cells endowed with such CARs are particularly suited for treating lymphomas and leukemia.
    Type: Grant
    Filed: March 19, 2015
    Date of Patent: April 17, 2018
    Assignee: CELLECTIS
    Inventor: Roman Galetto
  • Monospecific and bispecific anti-IGF-1R and anti-ErbB3 antibodies
    Patent number: 9938346
    Abstract: Provided are monospecific and bispecific antibodies that are useful as anti-neoplastic agents and that bind specifically to human IGF-1R and human ErbB3. Exemplary antibodies inhibit signal transduction through either or both of IGF-1R and ErbB3. Exemplary polyvalent proteins comprise at least one anti-IGF-1R binding site and at least one anti-ErbB3 binding site. In certain embodiments the binding sites may be linked through an immunoglobulin constant region. AntiErbB3 and anti-IGF-1R antibodies (e.g., monoclonal antibodies) are also provided.
    Type: Grant
    Filed: August 26, 2016
    Date of Patent: April 10, 2018
    Assignee: Merrimack Pharmaceuticals, Inc.
    Inventors: Jason Baum, Bryan Johnson, Alexey Alexandrovich Lugovskoy, Lihui Xu, Neeraj Kohli, Jonathan Basil Fitzgerald, Sharlene Adams
  • Anti CD37 antibodies
    Patent number: 9932399
    Abstract: Chimeric and humanized anti-CD37 antibodies and pharmaceutical compositions containing them are useful for the treatment of B cell malignancies and autoimmune and inflammatory diseases that involve B cells in their pathology.
    Type: Grant
    Filed: April 22, 2015
    Date of Patent: April 3, 2018
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Karl-Heinz Heider, Eric Borges, Elinborg Ostermann